Jianqi Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jianqi Zhao has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Chunhong Huang
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang 330006, China
4 shared publications - Xiao Shi
Queen Mary School, Jiangxi Medical College, Nanchang University, Nanchang 330006, China
3 shared publications - Guangyao Liu
Jiangxi Provincial Key Laboratory of Tumor Biology, Nanchang University, Nanchang 330031, China
2 shared publications - Linfeng Wang
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang 330006, China
2 shared publications - Meiling Liu
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang 330006, China
2 shared publications - Yang Yang
Affiliation Health Management Center, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
2 shared publications
Latest Publications
- Open Access
- 7 July 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (7) , 1050
Deciphering the Multi-Target Mechanisms of Sheshang Jiedu Decoction Against Snake Envenomation-Induced Acute Hepatic Dysfunction: An Integrated Multi-Omics Study
Objective: This study aimed to experimentally validate the hepatoprotective efficacy of Sheshang Jiedu Decoction (SSJDD) against Deinagkistrodon acutus (D. acutus) venom-induced acute liver injury (ALI) and systematically elucidate its multicomponent, multitarget mechanisms using an integrated multi−omics strategy. Methods: SSJDD constituents and serum-absorbed metabolites were profiled using UPLC-Q-Exactive HFX MS, and potential targets were predicted via network pharmacology. An in vivo model was established by intraperitoneally injecting Kunming mice with D. acutus venom, followed by a 7-day oral SSJDD intervention. The therapeutic efficacy was assessed by histopathological examination, serological analysis, and detection of oxidative stress markers in liver tissues. Label-free quantitative proteomics was performed on murine livers to map dynamic protein alterations and signaling cascades. Results: Integrated metabolomic and network analyses identified 15 primary active serum metabolites converging on core regulatory targets, including TP53, AKT1, and CASP3. In vivo, SSJDD dose-dependently ameliorated venom-induced lobular necrosis, suppressed elevated transaminases, and restored redox homeostasis without intrinsic hepatotoxicity. Quantitative proteomics revealed that venom triggered profound acute oxidative stress and coagulopathies, progressing to chronic metabolic disruption. SSJDD intervention substantially attenuated these proteomic alterations—reducing differentially expressed proteins by 84%—steering the hepatic microenvironment toward baseline homeostasis. Enrichment analyses demonstrated that these effects were primarily driven by modulating the coagulation-inflammation axis and the PI3K−Akt signaling pathway. Conclusions: SSJDD provides robust protection against D. acutus venom-induced ALI. Its active metabolites synergistically orchestrate hepatic repair and restore microenvironmental stability, primarily by targeting the PI3K−Akt pathway and regulating the coagulation-inflammation axis.
- 7 July 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (7) , 1050
Open AccessDeciphering the Multi-Target Mechanisms of Sheshang Jiedu Decoction Against Snake Envenomation-Induced Acute Hepatic Dysfunction: An Integrated Multi-Omics Study
Objective: This study aimed to experimentally validate the hepatoprotective efficacy of Sheshang Jiedu Decoction (SSJDD) against Deinagkistrodon acutus (D. acutus) venom-induced acute liver injury (ALI) and systematically elucidate its multicomponent, multitarget mechanisms using an integrated multi−omics strategy. Methods: SSJDD constituents and serum-absorbed metabolites were profiled using UPLC-Q-Exactive HFX MS, and potential targets were predicted via network pharmacology. An in vivo model was established by intraperitoneally injecting Kunming mice with D. acutus venom, followed by a 7-day oral SSJDD intervention. The therapeutic efficacy was assessed by histopathological examination, serological analysis, and detection of oxidative stress markers in liver tissues. Label-free quantitative proteomics was performed on murine livers to map dynamic protein alterations and signaling cascades. Results: Integrated metabolomic and network analyses identified 15 primary active serum metabolites converging on core regulatory targets, including TP53, AKT1, and CASP3. In vivo, SSJDD dose-dependently ameliorated venom-induced lobular necrosis, suppressed elevated transaminases, and restored redox homeostasis without intrinsic hepatotoxicity. Quantitative proteomics revealed that venom triggered profound acute oxidative stress and coagulopathies, progressing to chronic metabolic disruption. SSJDD intervention substantially attenuated these proteomic alterations—reducing differentially expressed proteins by 84%—steering the hepatic microenvironment toward baseline homeostasis. Enrichment analyses demonstrated that these effects were primarily driven by modulating the coagulation-inflammation axis and the PI3K−Akt signaling pathway. Conclusions: SSJDD provides robust protection against D. acutus venom-induced ALI. Its active metabolites synergistically orchestrate hepatic repair and restore microenvironmental stability, primarily by targeting the PI3K−Akt pathway and regulating the coagulation-inflammation axis.
- Open Access
- 12 June 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (6) , 929
Meloxicam Alleviates Sepsis-Induced Lung Injury by Inhibiting Pyroptosis Through CBP/TXNIP/p38 Signaling Pathway
Background: Macrophage pyroptosis contributes substantially to sepsis-induced lung injury, yet effective therapeutic strategies remain limited. This study aimed to determine the protective effects of meloxicam, a non-steroidal anti-inflammatory drug, and the underlying mechanisms in this context. Methods:In vivo, CLP mice were treated with meloxicam (20 mg/kg). In vitro, LPS-primed macrophages were stimulated with ATP or nigericin in the presence or absence of meloxicam. Levels of pyroptosis-associated proteins (cleaved Caspase-1, mature IL-1β, GSDMD-NT), NLRP3 inflammasome assembly, and the CBP/TXNIP/p38 signaling axis were assessed by Western blot. Mitochondrial membrane potential (ΔΨm) and intracellular ROS were measured. Overexpression of COX-2, TXNIP, and CBP was also performed. Results: Meloxicam significantly improved survival, reduced lung injury, and suppressed pyroptosis-associated proteins in CLP mice. In vitro, meloxicam dose-dependently enhanced macrophage viability and reduced LDH, IL-1β, and IL-18 release. The protective effects of meloxicam were mediated by inhibition of NLRP3 inflammasome priming and assembly, disruption of NLRP3-ASC-pro-Caspase-1 complex formation, and suppression of ASC oligomerization. Meloxicam also inhibited the CBP/TXNIP/p38 axis, an effect reversed by TXNIP or CBP overexpression. Furthermore, meloxicam restored ΔΨm and reduced ROS accumulation; these effects were abrogated by the ROS inducer imiquimod. Importantly, the anti-pyroptotic effects of meloxicam were independent of COX-2 inhibition. Conclusions: These findings expand the pharmacological profile of meloxicam and support its repurposing as a therapeutic agent for sepsis-associated lung injury.
- 12 June 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (6) , 929
Open AccessMeloxicam Alleviates Sepsis-Induced Lung Injury by Inhibiting Pyroptosis Through CBP/TXNIP/p38 Signaling Pathway
Background: Macrophage pyroptosis contributes substantially to sepsis-induced lung injury, yet effective therapeutic strategies remain limited. This study aimed to determine the protective effects of meloxicam, a non-steroidal anti-inflammatory drug, and the underlying mechanisms in this context. Methods:In vivo, CLP mice were treated with meloxicam (20 mg/kg). In vitro, LPS-primed macrophages were stimulated with ATP or nigericin in the presence or absence of meloxicam. Levels of pyroptosis-associated proteins (cleaved Caspase-1, mature IL-1β, GSDMD-NT), NLRP3 inflammasome assembly, and the CBP/TXNIP/p38 signaling axis were assessed by Western blot. Mitochondrial membrane potential (ΔΨm) and intracellular ROS were measured. Overexpression of COX-2, TXNIP, and CBP was also performed. Results: Meloxicam significantly improved survival, reduced lung injury, and suppressed pyroptosis-associated proteins in CLP mice. In vitro, meloxicam dose-dependently enhanced macrophage viability and reduced LDH, IL-1β, and IL-18 release. The protective effects of meloxicam were mediated by inhibition of NLRP3 inflammasome priming and assembly, disruption of NLRP3-ASC-pro-Caspase-1 complex formation, and suppression of ASC oligomerization. Meloxicam also inhibited the CBP/TXNIP/p38 axis, an effect reversed by TXNIP or CBP overexpression. Furthermore, meloxicam restored ΔΨm and reduced ROS accumulation; these effects were abrogated by the ROS inducer imiquimod. Importantly, the anti-pyroptotic effects of meloxicam were independent of COX-2 inhibition. Conclusions: These findings expand the pharmacological profile of meloxicam and support its repurposing as a therapeutic agent for sepsis-associated lung injury.
- Open Access
Geographic Variation in Venom Proteome and Toxicity Profiles of Chinese Naja atra: Implications for Antivenom Optimization
Differences in venom within snake species can affect the efficacy of antivenom, but how this variation manifests across broad geographical scales remains poorly understood. Naja atra envenoming causes severe morbidity in China, yet whether intraspecific venom variation exists across mainland regions is unknown. We collected venom samples from seven biogeographical regions (spanning > 2000 km latitude). Venom lethality, systemic toxicity (organ damage biomarkers and coagulopathy), and histopathology of major organs were assessed. Neutralization by antivenom and label-free quantitative proteomics (LC-MS/MS) were also performed. The results revealed a non-uniform LD50, with venom from Yunnan exhibiting the highest lethality (2.1-fold higher than venom from Zhejiang, p < 0.001). Commercial antivenom showed lower neutralization efficacy against the venom from the Yunnan, Guangxi, and Guangdong regions. Regarding organ damage and coagulopathy, venom from Yunnan caused severe liver damage, while venom from the Zhejiang region induced significant coagulopathy. Finally, proteomic profiles identified 175 proteins: venom from Yunnan was dominated by phospholipases, contrasting with eastern regions (Anhui/Zhejiang: cytotoxins CTXs > 30%). Venom from Guangdong contained higher levels of the weak neurotoxin NNAM2 (5.2%). Collectively, significant geographical divergence exists in Chinese Cobra venom composition, systemic toxicity, and antivenom susceptibility, driven by differential expression of key toxins. Our study provides a molecular basis for precision management of snakebites, and we call for optimized antivenom production tailored to regional variations.
Open AccessGeographic Variation in Venom Proteome and Toxicity Profiles of Chinese Naja atra: Implications for Antivenom Optimization
Differences in venom within snake species can affect the efficacy of antivenom, but how this variation manifests across broad geographical scales remains poorly understood. Naja atra envenoming causes severe morbidity in China, yet whether intraspecific venom variation exists across mainland regions is unknown. We collected venom samples from seven biogeographical regions (spanning > 2000 km latitude). Venom lethality, systemic toxicity (organ damage biomarkers and coagulopathy), and histopathology of major organs were assessed. Neutralization by antivenom and label-free quantitative proteomics (LC-MS/MS) were also performed. The results revealed a non-uniform LD50, with venom from Yunnan exhibiting the highest lethality (2.1-fold higher than venom from Zhejiang, p < 0.001). Commercial antivenom showed lower neutralization efficacy against the venom from the Yunnan, Guangxi, and Guangdong regions. Regarding organ damage and coagulopathy, venom from Yunnan caused severe liver damage, while venom from the Zhejiang region induced significant coagulopathy. Finally, proteomic profiles identified 175 proteins: venom from Yunnan was dominated by phospholipases, contrasting with eastern regions (Anhui/Zhejiang: cytotoxins CTXs > 30%). Venom from Guangdong contained higher levels of the weak neurotoxin NNAM2 (5.2%). Collectively, significant geographical divergence exists in Chinese Cobra venom composition, systemic toxicity, and antivenom susceptibility, driven by differential expression of key toxins. Our study provides a molecular basis for precision management of snakebites, and we call for optimized antivenom production tailored to regional variations.
- Open Access
Combination of Rhamnetin and RXP03 Mitigates Venom-Induced Toxicity in Murine Models: Preclinical Insights into Dual-Target Antivenom Therapy
Snakebite is a significant global public health challenge, and the limited application of antivenom has driven the exploration of novel therapies. Combination therapy using small-molecule drugs targeting phospholipases A2 (PLA2) and metalloproteinases (SVMP) in venom shows great potential. Although Rhamnetin and RXP03 exhibit notable anti-phospholipase and anti-metalloproteinase activities, respectively, their antiophidic potential remains poorly explored. This study aims to evaluate the inhibitory effects of Rhamnetin and RXP03 on snake venom toxicity. Methodologically, we conducted in vitro enzymatic assays to quantify PLA2/SVMP inhibition, murine models of envenomation (subcutaneous/intramuscular venom injection) to assess local tissue damage and systemic toxicity, and histopathological/biochemical analyses. In vitro experiments demonstrated that Rhamnetin effectively inhibited PLA2 activity while RXP03 showed potent suppression of SVMP activity, with their combination significantly reducing venom-induced hemorrhagic activity. In murine models, the combined therapy markedly alleviated venom-triggered muscle toxicity and ameliorated oxidative stress. Furthermore, the combination enhanced motor performance and survival rate in mice, improved serum biochemical parameters, corrected coagulation disorders, and attenuated pathological damage in liver, kidney, heart, and lung tissues. This research demonstrates that dual-targeted therapy against metalloproteinases and phospholipases in snake venom can effectively prevent a series of injuries caused by snake venom. Collectively, the combined application of Rhamnetin and RXP03 exhibits significant inhibitory effects on a variety of venom-induced toxicities, providing pharmacological evidence for the development of antivenom therapies. However, the efficacy validation in this study was limited to murine models, and there is a discrepancy with clinical needs for delayed treatment in real-world envenomation scenarios. Despite these limitations, the findings provide robust preclinical evidence supporting the Rhamnetin–RXP03 combination therapy as a cost-effective, broad-spectrum antivenom strategy. Future studies are required to optimize dosing regimens and evaluate clinical translatability.
Open AccessCombination of Rhamnetin and RXP03 Mitigates Venom-Induced Toxicity in Murine Models: Preclinical Insights into Dual-Target Antivenom Therapy
Snakebite is a significant global public health challenge, and the limited application of antivenom has driven the exploration of novel therapies. Combination therapy using small-molecule drugs targeting phospholipases A2 (PLA2) and metalloproteinases (SVMP) in venom shows great potential. Although Rhamnetin and RXP03 exhibit notable anti-phospholipase and anti-metalloproteinase activities, respectively, their antiophidic potential remains poorly explored. This study aims to evaluate the inhibitory effects of Rhamnetin and RXP03 on snake venom toxicity. Methodologically, we conducted in vitro enzymatic assays to quantify PLA2/SVMP inhibition, murine models of envenomation (subcutaneous/intramuscular venom injection) to assess local tissue damage and systemic toxicity, and histopathological/biochemical analyses. In vitro experiments demonstrated that Rhamnetin effectively inhibited PLA2 activity while RXP03 showed potent suppression of SVMP activity, with their combination significantly reducing venom-induced hemorrhagic activity. In murine models, the combined therapy markedly alleviated venom-triggered muscle toxicity and ameliorated oxidative stress. Furthermore, the combination enhanced motor performance and survival rate in mice, improved serum biochemical parameters, corrected coagulation disorders, and attenuated pathological damage in liver, kidney, heart, and lung tissues. This research demonstrates that dual-targeted therapy against metalloproteinases and phospholipases in snake venom can effectively prevent a series of injuries caused by snake venom. Collectively, the combined application of Rhamnetin and RXP03 exhibits significant inhibitory effects on a variety of venom-induced toxicities, providing pharmacological evidence for the development of antivenom therapies. However, the efficacy validation in this study was limited to murine models, and there is a discrepancy with clinical needs for delayed treatment in real-world envenomation scenarios. Despite these limitations, the findings provide robust preclinical evidence supporting the Rhamnetin–RXP03 combination therapy as a cost-effective, broad-spectrum antivenom strategy. Future studies are required to optimize dosing regimens and evaluate clinical translatability.